Future of Cell Therapy in the Regenerative Medicine Market
This Frost & Sullivan research service analyses the current trends, forecasts and the external factors influencing the global cell therapy market. It also studies top participants in the market, disruptive pipeline products, and the opportunities in combination therapy. In addition, it provides a detailed commercialization analysis of research and development (R&D), manufacturing, and funding considerations.
In this research, Frost & Sullivan's expert analysts thoroughly examine the following market segments:
Stem cell therapy
Stem cell-gene therapy
They also analyze the following geographic segments in detail:
North America (Canada, the United States of America)
Europe (Germany, United Kingdom, Benelux, Spain, France, Scandinavia, Italy)
Asia-Pacific (Japan, Association of South East Asian Nations (ASEAN), China, India)
Rest of the world (Brazil, Africa, Russia)
Late Stage Hybrid Cell Therapy to Disrupt the Overall Cell Therapy Market
Heavy investments in the development and commercialization of cell therapy products have made North America the forerunner with 50 percent share in the global cell therapy market. However, the Asia-Pacific market is growing at a faster rate, on the strength of the intensified R&D activity in Japan and South Korea. Meanwhile, the pressure to reduce the cost of care for aging population has driven the governments in some countries including, Japan, Canada, and the United States to create programs to facilitate the rapid commercialization of therapy products. Accordingly, the United States and Japan have fast tracked R&D in treatments that employ highly curative stem cell, cell-gene, and immunotherapy. Many governments in North America and the Asia-Pacific are drafting policies to encourage the establishment of centers of excellence, manufacturing infrastructure and research networks to ensure profitable commercialization of products.
Despite these external drivers, the market is hindered to some extent by the lack of viable manufacturing infrastructure that supports the mass production of quality cell therapy products. Therefore, large-scale manufacturing units for autologous cell therapy and combination therapy products are necessary to meet the market demand. Manufacturers across segments could emulate the sustainable manufacturing models currently used by the market leaders to develop strategic facilities and deploy automated machinery to increase the output.
Nevertheless, the cell therapy market is growing exponentially with technical advancements in various areas. Commercializing late stage hybrid therapy will disrupt the mainstream cellular therapy market. Allogeneic therapy is expected to enjoy significant uptake as the overall market perceptibly shifts from autologous to allogeneic treatments. Market participants are also striving to find treatments for chronic diseases, with close to 50 percent of their pipeline therapy focused on oncology. Evidently, innovative treatments and sustainable manufacturing models are critical for success in this market.
Electronic Access - Site License Fulfilled By Publisher
Electronic Access - Global site License Fulfilled By Publisher